Why Orchard Therapeutics Stock Is Soaring Today
A buyout offer is fueling a rise in the company's shares today.
Is Ardelyx is A Buy After Slip in Early 2022
Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them